Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 15634760)


Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K.

Mol Cancer Res. 2004 Dec;2(12):712-21.


Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.

Trembley JH, Unger GM, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton JW, Kren BT, Ahmed K.

Mol Cell Biochem. 2011 Oct;356(1-2):21-35. doi: 10.1007/s11010-011-0943-x. Epub 2011 Jul 15.


Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy.

Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K.

Mol Cell Biochem. 2005 Jun;274(1-2):77-84.


Targeting CK2 for cancer therapy.

Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K.

Anticancer Drugs. 2005 Nov;16(10):1037-43. Review.


CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, Arun P, Lu H, Korman V, Unger G, Ahmed K, Van Waes C, Chen Z.

Clin Cancer Res. 2010 Apr 15;16(8):2295-307. doi: 10.1158/1078-0432.CCR-09-3200. Epub 2010 Apr 6.


Response of cancer cells to molecular interruption of the CK2 signal.

Wang H, Davis A, Yu S, Ahmed K.

Mol Cell Biochem. 2001 Nov;227(1-2):167-74.


Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells.

Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K.

Mol Cancer Ther. 2007 Mar;6(3):1006-12.


Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice.

Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S.

FASEB J. 2005 Dec;19(14):2042-4. Epub 2005 Oct 17.


Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.

Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC.

Clin Cancer Res. 2003 Jul;9(7):2826-36.


Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.

Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.

Clin Cancer Res. 2004 Jul 15;10(14):4858-64.


Protein B23/nucleophosmin/numatrin nuclear dynamics in relation to protein kinase CK2 and apoptotic activity in prostate cells.

Wang G, Pan Y, Ahmad KA, Ahmed K.

Biochemistry. 2010 May 11;49(18):3842-52. doi: 10.1021/bi9021928.


EphB4 expression and biological significance in prostate cancer.

Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS.

Cancer Res. 2005 Jun 1;65(11):4623-32.


Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.

Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SP.

J Urol. 2004 Sep;172(3):1140-4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk